ATE442439T1 - Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren - Google Patents

Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren

Info

Publication number
ATE442439T1
ATE442439T1 AT96903473T AT96903473T ATE442439T1 AT E442439 T1 ATE442439 T1 AT E442439T1 AT 96903473 T AT96903473 T AT 96903473T AT 96903473 T AT96903473 T AT 96903473T AT E442439 T1 ATE442439 T1 AT E442439T1
Authority
AT
Austria
Prior art keywords
melanoma
antigene
diagnostic
application
therapeutic procedures
Prior art date
Application number
AT96903473T
Other languages
English (en)
Inventor
Paul Robbins
Steven Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE442439T1 publication Critical patent/ATE442439T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
AT96903473T 1995-01-10 1996-01-11 Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren ATE442439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/370,909 US5843648A (en) 1995-01-10 1995-01-10 P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
PCT/US1996/000473 WO1996021734A2 (en) 1995-01-10 1996-01-11 P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods

Publications (1)

Publication Number Publication Date
ATE442439T1 true ATE442439T1 (de) 2009-09-15

Family

ID=23461684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903473T ATE442439T1 (de) 1995-01-10 1996-01-11 Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren

Country Status (8)

Country Link
US (1) US5843648A (de)
EP (1) EP0871725B1 (de)
JP (1) JP4223072B2 (de)
AT (1) ATE442439T1 (de)
AU (1) AU705992B2 (de)
CA (1) CA2209990A1 (de)
DE (1) DE69638024D1 (de)
WO (1) WO1996021734A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876972A (en) * 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6872518B2 (en) * 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
EP1187849A1 (de) * 1999-05-25 2002-03-20 Human Genome Sciences, Inc. Meth1 und meth2 polynukleotide und polypeptide
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
EP1268763A2 (de) * 2000-03-28 2003-01-02 University Of Rochester Verfahren zur herstellung einer bibliothek und zur selektion von polynukleotiden
US20030194696A1 (en) * 2000-03-28 2003-10-16 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
EA013944B1 (ru) * 2001-02-20 2010-08-30 Орто-Макнейл Фармасьютикал, Инк. Способ получения неприродной антигенпрезентирующей клеточной линии и применение линии для лечения опухолей
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US6951720B2 (en) * 2001-05-10 2005-10-04 San Diego State University Foundation Use of phosphorothiolate polynucleotides in ligating nucleic acids
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
EP2199406A1 (de) * 2003-05-01 2010-06-23 Veridex, LLC Intraoperativer Lymphknotentest
AU2009289277B2 (en) 2008-09-02 2014-09-04 Chu Nantes Novel melanoma antigen peptide and uses thereof
WO2010028672A1 (en) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
EP3607974A1 (de) * 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Krebsimpfstoffe und verfahren zur behandlung unter verwendung davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5134227A (en) * 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
CA2128424A1 (en) * 1992-01-21 1993-07-22 Pierre G. Coulie Method for determining cytolytic t cell precursors
EP0658113B1 (de) * 1992-08-31 2004-10-20 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
ES2172287T4 (es) * 1992-12-22 2003-04-16 Ludwig Inst Cancer Res Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
AU6496094A (en) * 1993-03-31 1994-10-24 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
EP0668350B2 (de) * 1994-02-16 2008-12-03 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma

Also Published As

Publication number Publication date
CA2209990A1 (en) 1996-07-18
WO1996021734A2 (en) 1996-07-18
EP0871725B1 (de) 2009-09-09
EP0871725A2 (de) 1998-10-21
AU705992B2 (en) 1999-06-03
WO1996021734A3 (en) 1996-11-28
JP4223072B2 (ja) 2009-02-12
DE69638024D1 (de) 2009-10-22
JPH11502405A (ja) 1999-03-02
AU4755496A (en) 1996-07-31
US5843648A (en) 1998-12-01

Similar Documents

Publication Publication Date Title
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
EP1630229A3 (de) Melanoma Antigene
EP2311952A3 (de) Antikörper gegen MART-1 Protein oder Fragmenten davon
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
TR199801722T2 (xx) Peptit imm�nojenler.
CA2290485A1 (en) Method for the production of non-immunogenic proteins
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
HUP0002176A2 (hu) Vakcinákban vagy diagnosztikai vizsgálatokban alkalmazható PRRSV-peptidszekvenciákat azonosító PRRSV-antigénhelyek
DE69028388D1 (de) Monoklonaler antikörper gegen ein neues humanes tumor assoziiertes antigen
GR1000477B (el) Νεο μονοκλωνικο αντισωμα κατα νεου αντιγονου που σχετιζεται με ανθρωπινους ογκους.
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69739981D1 (de) Streptococcus pneumoniae-Antigene und Impfstoffe
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
BR9106303A (pt) Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
AR033832A1 (es) Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
RU94046414A (ru) Моноклональные антитела к гликопротеину р, их получение и применение, продуцирующие их клетки, иммунологический диагностический набор на их основе, терапевтический состав
DK0610335T3 (da) Fremgangsmåder til udformning af rekombitope peptider
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE86633T1 (de) Snrnp-a-antigen und fragmente davon.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties